利奈唑胺替代乙胺丁醇治疗肺结核的2期试验
这项在韩国三家医院开展的2期、多中心、随机、开放标签试验,将429例痰菌阳性且对利福平敏感的肺结核患者随机分为对照组(乙胺丁醇2个月)、利奈唑胺2周组和利奈唑胺4周组。短期利奈唑胺未提高8周培养转阴率,但安全性及耐药分析提示其可能用于缩短药物敏感结核疗程。
要点
- 短期利奈唑胺替代乙胺丁醇未提高8周痰培养转阴率。
- 三组不良事件发生率相似,未发现利奈唑胺耐药。
- 利奈唑胺在缩短药物敏感结核疗程方面可能有潜在作用。
核心结论
- 短期使用利奈唑胺替代乙胺丁醇未观察到8周治疗时培养转阴率升高。
- 安全性分析和耐药谱提示利奈唑胺在缩短药物敏感结核治疗方面可能有潜在作用。
研究设计与样本
- 2期、多中心、随机、开放标签试验,在韩国首尔大学三家附属医院及国家医疗中心进行。
- 纳入20-80岁、痰菌阳性、对利福平敏感且当前治疗≤7天的肺结核患者,按1:1:1随机分为三组。
- 对照组接受乙胺丁醇2个月联合异烟肼、利福平、吡嗪酰胺;利奈唑胺2周组和4周组分别以利奈唑胺600 mg/天替代乙胺丁醇2周或4周。
- 共入组429例,428例随机分配(对照组142例、利奈唑胺2周组143例、利奈唑胺4周组143例),401例纳入改良意向治疗分析。
主要发现
- 未在任何患者中检测到利奈唑胺耐药。
关键数值与推荐
- 主要终点为治疗8周时液体培养基痰培养转阴率,采用改良意向治疗人群分析。
临床怎么用
- 对于药物敏感肺结核,短期利奈唑胺替代乙胺丁醇未显示提高8周培养转阴率,不宜据此常规替换。
- 利奈唑胺安全性可接受且未发现耐药,但用于缩短疗程仍需进一步研究。
局限性
- 为2期探索性试验,样本量有限,主要终点为8周培养转阴率而非最终治疗结局。
- 开放标签设计可能引入偏倚。
- 研究仅在韩国进行,结果外推需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Linezolid improves the treatment outcomes of multidrug-resistant tuberculosis substantially. We investigated whether use of linezolid instead of ethambutol increases the proportion of sputum culture conversion at 8 weeks of treatment in patients with pulmonary tuberculosis. METHODS: We did a phase 2, multicentre, randomised, open-label trial for patients with pulmonary tuberculosis at the three affiliated hospitals to Seoul National University and National Medical Center (Seoul-Seongnam, South Korea). Patients, aged 20-80 years, with a positive sputum for pulmonary tuberculosis, but without resistance to rifampicin, and current treatment administered for 7 days or fewer, were randomly assigned at a 1:1:1 ratio into three groups. The control group received ethambutol (2 months) with isoniazid, rifampicin, and pyrazinamide. The second group used linezolid (600 mg/day) for 2 weeks and the third group for 4 weeks instead of ethambutol for 2 months. We used a minimisation method to randomise, and stratified according to institution, cavitation on chest radiographs, and diabetes. The primary endpoint was the proportion of patients with negative culture conversion of sputum in liquid media after 8 weeks of treatment. The results of this trial were analysed primarily in the modified intention-to-treat population. The trial is registered with ClinicalTrials.gov, number NCT01994460. FINDINGS: Between Feb 19, 2014, and Jan 13, 2017, a total of 429 patients were enrolled and 428 were randomly assigned into either the control group (142 patients), the linezolid 2 weeks group (143 patients), or the linezolid 4 weeks group (143 patients). Among them, 401 were eligible for primary efficacy analyses. In the modified intention-to-treat analyses, negative cultures in liquid media at 8 weeks of treatment were observed in 103 (76·9%) of 134 control patients, 111 (82·2%) of 135 in the linezolid 2 weeks group, and 100 (75·8%) of 132 in the linezolid 4 weeks groups. The difference from the control group was 5.4% (95% CI -4·3 to 15·0, p=0·28) for the linezolid 2 weeks group and -1·1% (-11·3 to 9·1, p=0·83) for the linezolid 4 weeks group. Numbers of patients who experienced at least one adverse event were similar across the groups (86 [62·8%] of 137 in control, 79 [57·2%] of 138 in the linezolid 2 weeks group, and 75 [62·0%] of 121 in the linezolid 4 weeks group). Resistance to linezolid was not identified in any patient. INTERPRETATION: Higher rates of culture conversion at 8 weeks of treatment with short-term use of linezolid were not observed. However, safety analyses and the resistance profile suggested the potential role of linezolid in shortening of treatment for drug-susceptible tuberculosis. FUNDING: Ministry of Health and Welfare, South Korea.
引用
- Lee JK, Lee JY, Kim DK, et al. Substitution of ethambutol with linezolid during the intensive phase of treatment of pulmonary tuberculosis: a prospective, multicentre, randomised, open-label, phase 2 trial. Lancet Infect Dis. 2018. PMID: 30477961. doi:10.1016/S1473-3099(18)30480-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。